Biotech’s February rebound delivered strong returns across the sector, but Averill stood out, powered by a soaring new IPO that helped drive the firm to double‑digit gains.One of Averill’s main long-short fund share classes gained 15.3 percent last month after losing money in January. It is now up 11.9 percent for the year, according to someone who has seen the results. Averill Madison, which emphasizes large-cap stocks, did even better, surging 18.7 percent for the month and 13.4 percent for th...
Continue Reading
Sign up for FREE to read the full article and access 132K+ alternative investment headlines.
Alternative Investment News